84228-49-9

Usage

Uses

Used in Pharmaceutical Industry:
METHYL 2-AMINO-5-CHLORO-3-NITROBENZOATE is used as an intermediate in the synthesis of various drugs and pharmaceuticals for its valuable anti-inflammatory and analgesic properties. This allows for the development of new medications that can effectively address pain and inflammation, improving patient care and treatment options.

Upstream product

• 67-56-1 methanol 
• 186581-53-3 diazomethane 
• 6324-51-2 2-amino-5-chloro-3-nitrobenzoic acid 
• 17630-76-1 5-chloroindole 2,3-dione 
• 635-21-2 5-chloroanthranilic acid 
• 573692-70-3 5-chloro-3-nitro-2-(2,2,2-trifluoroacetyl)aminobenzoic acid 
• 648939-10-0 5-chloro-2-(2,2,2-trifluoroacetyl)aminobenzoic acid 

Downstream Products

• 314248-61-8 methyl 2,3-diamino-5-chlorobenzoate 
• 6324-51-2 2-amino-5-chloro-3-nitrobenzoic acid 
• 40545-37-7 2-amino-5-chloro-3-nitrobenzamide 
• 573692-41-8 2,3-diamino-5-chlorobenzamide 

Relevant academic research and scientific papers

Design and synthesis of 2-(4,5,6,7-tetrahydrothienopyridin-2-yl)-benzoimidazole carboxamides as novel orally efficacious Poly(ADP-ribose)polymerase (PARP) inhibitors

The nuclear protein poly(ADP-ribose) polymerases-1/2 (PARP-1/2) are involved in DNA repair damaged by endogenous or exogenous process. And PARP-1/2 inhibitors have been proved to be clinically efficacious for DNA repair deficient tumors in the past decade

COMPOUNDS USEFUL AS ANTIBIOTIC TOLERANCE INHIBITORS

The disclosure provides compounds and pharmaceutical compositions of the compounds useful for treating chronic and acute bacterial infections. Certain of the compounds are compounds and salts of general Formula VIII Certain compounds of this disclosure are MvfR inhibitors. MvfR inhibitors reduce the formation of antibiotic tolerant bacterial strains and are useful for treating Gram-negative bacterial infections and reducing the virulence of Pseudomonas aeruginosa. Methods of treating bacterial infections in a patient, including Pseudomonas aeruginosa infections, are also provided by the disclosure.

DIHYDROOROTATE DEHYDROGENASE INHIBITORS

The invention relates to compounds of formula (I) wherein R1, R2, X1, X2, Y, Ra, Rb, Q have the meanings given in claim 1. The compounds are useful e.g. in the treatment of autoimmune disorders, such as multiple sclerosis and also in the treatment of cancer disorders.

Synthesis and SAR of novel di- and trisubstituted 1,4-dihydroquinoxaline-2,3-diones related to licostinel (Acea 1021) as NMDA/glycine site antagonists

A series of novel di- and trisubstituted 1,4-dihydroquinoxaline-2,3-diones (QXs) related to licostinel (Acea 1021) was synthesized and evaluated as antagonists for the glycine site of the N-methyl-D-asparate (NMDA) receptor. The in vitro potency of these